维多珠单抗
|
|
- CAS号:
- 943609-66-3
- 英文名:
- Vedolizumab
- 英文别名:
- Vedolizumab;Vedolizumab USP/EP/BP;Vedolizumab (anti-α4β7-integrin);Research Grade Vedolizumab(DHC98802)
- 中文名:
- 维多珠单抗
- 中文别名:
- 维多珠单抗;维多组单抗;VEDOLIZUMAB ( 维多组单抗 )
- CBNumber:
- CB54187577
- 分子式:
- 分子量:
- 0
- MOL File:
- Mol file
|
|
|
维多珠单抗化学性质
-
储存条件:
-
Store at -80°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
形态:
-
Solid
-
|
-
颜色:
-
White to off-white
-
|
维多珠单抗性质、用途与生产工艺
维多珠单抗(vedolizumab)是一种全人源化单克隆抗体,特异性拮抗α4β7整合素,抑制α4β7整合素对肠道黏膜细胞粘附分子MAdCAM-1的结合。
2014年5月,美国FDA批准维多珠单抗上市,用于对常规疗法或一种TNF-α拮抗剂不耐受、或不再响应、或响应不足的中度至重度活动性溃疡性结肠炎(UC)或克罗恩病(Crohn's disease,CD)成人患者的治疗。
Vedolizumab是一种靶向α4β7整联蛋白 (integrin) 的人源化单克隆抗体,用于溃疡性结肠炎和克罗恩病的相关研究。
Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC
50
=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC
50
=0.02-0.06 g/mL) and fibronectin (IC
50
=0.02 g/mL), but not vascular cell adhesion molecule 1.
Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups.
维多珠单抗
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/08/19 | HY-P9911A | Vedolizumab (anti-α4β7-integrin) | | 1 mg | 1700元 |
2024/08/19 | HY-P9911A | Vedolizumab (anti-α4β7-integrin) | | 5 mg | 4500元 |
943609-66-3, 维多珠单抗 相关搜索:
- 抗体类配体
- 高纯试剂
- 单抗系列
- 药物对照抗体
- 化学试剂
- 对照品
- 单抗22
- 原料药
- 943609-66-6
- 维多组单抗
- VEDOLIZUMAB ( 维多组单抗 )
- 维多珠单抗
- 943609-66-3
- Vedolizumab (anti-α4β7-integrin)
- Research Grade Vedolizumab(DHC98802)
- Vedolizumab USP/EP/BP
- Vedolizumab